Share This Article:

Oral Desmopressin in the Management of Adults with Nocturia

Abstract Full-Text HTML Download Download as PDF (Size:121KB) PP. 72-75
DOI: 10.4236/oju.2011.14015    3,022 Downloads   5,946 Views  


We investigated the efficacy of oral desmopressin in the treatment of adult nocturia. In an analytical study between 2007-2009 in Zahedan-Iran, Thirty patients ≥55 years with verified nocturia (≥two voids/night) were enrolled. Patients with a history of an obstructive cause of nocturia, those with diseases getting worse by the anti-diuretic affect of desmopressin and those with well-defined curable causes (e.g. cystitis) were excluded. Patients received 0.2 mg of oral desmopressin at bed time for a period of 3 weeks. p < 0.05 was taken as the significant level. All 30 patients enrolled completed the trial. Fourteen (47 %) patients receiving desmopressin had fewer than half the number of nocturnal voids relative to base line (p < 0.001). The mean number of nocturnal voids decreased from 4.6 to 2.4 (p < 0.001). Fatigue (10%), headache (3%) and dizziness (3%) were reported. All adverse events were of mild intensity and there were no instances of hyponatremia. Oral desmopressin is an effective treatment in patients with nocturia and is well-tolerated.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Gooran, S. Nasirmohtaram, M. Mohseni and B. Narouie, "Oral Desmopressin in the Management of Adults with Nocturia," Open Journal of Urology, Vol. 1 No. 4, 2011, pp. 72-75. doi: 10.4236/oju.2011.14015.


[1] P. van Kerrebroeck, P. Abrams, D. Chaikin, et al., “Standardisation Sub-Committee of the International Continence Society. The Standardisation of Terminology in Nocturia: Report from the Standardisation Sub-Committee of the International Continence Society,” Neurourology and Urodynamics, Vol. 21, No. 2, 2002, pp. 179-183. doi:10.1002/nau.10053
[2] F. Y. Chen, Y. T. Dai, C. K. Liu, et al., “Perception of Nocturia and Medical Consulting Behavior among community-Dwelling Women,” International Urogynecology Journal and Pelvic Floor Dysfunction, Vol. 18, No. 4, 2007, pp. 431-436. doi:10.1007/s00192-006-0167-x
[3] R. Lundgren, “Nocturia: A New Perspective on an Old Symptom,” Scandinavian Journal of Urology and Nephrology, Vol. 38, No. 2, 2004, pp. 112-116. doi:10.1080/00365590310020033
[4] Y. Homma, “Classification of Nocturia in the Adult and Elderly Patient: A Review of Clinical Criteria and Selected Literature,” BJU International, Vol. 96, Supplement 1, 2005, pp. 8-14. doi:10.1111/j.1464-410X.2005.05655.x
[5] R. B. Stewart, M. More, F. E. May, et al., “Nocturia a Risk Factor for Falls in the Elderly,” Journal of the American Geriatrics Society, Vol. 40, No. 12, 1992, pp. 1217-1220.
[6] S. P. Marinkovic, L. M. Gillen and S. L. Stanton, “Managing Nocturia,” British Medical Journal, Vol. 328, No. 7447, 2004, pp. 1063-1066. doi:10.1136/bmj.328.7447.1063
[7] R. Asplund and H. Aberg, “Diurnal Variation in the Levels of Antidiuretic Hormone in the Elderly,” Journal of Internal Medicine, 1991, Vol. 229, No. 2, pp. 131-134. doi:10.1111/j.1365-2796.1991.tb00320.x
[8] R. Asplund, “The Nocturnal Polyuria Syndrome (NPS),” General Pharmacology, Vol. 26, No. 6, 1995, pp. 1203-1209. doi:10.1016/0306-3623(94)00310-J
[9] M. Miller, “Nocturnal Polyuria in Older People: Pathophysiology and Clinical Implications,” Journal of the American Geriatrics Society, Vol. 48, No. 10, 2000, pp. 1321-1329.
[10] J. L. Kirkland, M. Lye, D. W. Levy and A. K. Banerjee, “Patterns of Urine Flow and Electrolyte Excretion in Healthy Elderly People,” British Medical Journal (Clinical Research Ed.), Vol. 287, No. 6406, 1983, pp. 1665-1667. doi:10.1136/bmj.287.6406.1665
[11] A. Mattiasson, P. Abrams, P. Van Kerrebroeck, et al., “Efficacy of Desmopressin in the Treatment of Nocturia: A Double-Blind Placebo-Controlled Study in Men,” BJU International, Vol. 89, No. 9, 2002, pp. 855-862. doi:10.1046/j.1464-410X.2002.02791.x
[12] S. Hunskaar, “Epidemiology of Nocturia,” BJU International, Vol. 96, Supplement 1, 2005, pp. 4-7. doi:10.1111/j.1464-410X.2005.05650.x
[13] H. Vilhardt, “Basic Pharmacology of Desmopressin: A Review,” Drug Investigation, Vol. 2, Supplement 5, 1990, pp. 2-8.
[14] R. Asplund and H. Aberg, “Desmopressin in Elderly Subjects with Increased Nocturnal Diuresis. A Two-Month Treatment Study,” Scandinavian Journal of Urology and Nephrology, Vol. 27, No. 1, 1993, pp. 77-82. doi:10.3109/00365599309180419
[15] R. Asplund, B. Sundberg and P. Bengtsson, “Oral Desmopressin for Nocturnal Polyuria in Elderly Subjects: A Double-Blind, Placebo-Controlled Randomized Exploratory Study,” BJU International, Vol. 83, No. 6, 1999, pp. 591-595. doi:10.1046/j.1464-410x.1999.00012.x
[16] R. Asplund and H. Aberg, “Health of the elderly with regard to sleep and nocturnal micturition,” Scandinavian Journal of Primary Health Care, Vol. 10, No. 2, 1992, pp. 98-104. doi:10.3109/02813439209014044
[17] S. B. Dimson, “Desmopressin as a Treatment for Enuresis,” The Lancet, Vol. 1, No. 8024, 1977, p. 1260.
[18] G. Lose, O. Lalos, R. M. Freeman and P. van Kerrebroeck, “Nocturia Study Group. Efficacy of Desmopressin (Minirin) in the Treatment of Nocturia: A Double-Blind Placebo-Controlled Study in Women,” American Journal of Obstetrics & Gynecology, Vol. 189, No. 4, 2003, pp. 1106-1113. doi:10.1067/S0002-9378(03)00593-3
[19] S. Salvatore, M. Soligo, F. Proietti, S. Citterio, W. Artibani and R. Milani, “Overactive Bladder Syndrome: Considerations in Pharmacotherapy and New Perspectives,” European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 120, No. 2, 2005, pp. 129-133. doi:10.1016/j.ejogrb.2004.10.014

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.